Literature DB >> 16688014

Management of seizures in the critically ill.

Panayiotis N Varelas1, Marianna Spanaki.   

Abstract

Seizures in a critically ill patient are not infrequent phenomena. Physicians are perplexed by the wide range of possible cranial or extracranial etiologies, alerted by the risk for further crucial organ compromise if seizures recur, and confused about the treatment options in an environment rich in complex drug interactions and multiple organ dysfunction. The advent of an armamentarium containing multiple new antiepileptic medications complicates the situation further, since several of them have less known mechanisms of action, side effects, or interactions with other intensive care unit (ICU) medications. This review contains useful information regarding the most common etiologies and treatment options for intensivists, consulting neurologists, neurosurgeons, or other specialized physicians treating ICU patients with seizures.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16688014     DOI: 10.1097/01.nrl.0000195827.34370.63

Source DB:  PubMed          Journal:  Neurologist        ISSN: 1074-7931            Impact factor:   1.398


  4 in total

Review 1.  Seizures and anticonvulsants after aneurysmal subarachnoid hemorrhage.

Authors:  Giuseppe Lanzino; Pietro Ivo D'Urso; Jose Suarez
Journal:  Neurocrit Care       Date:  2011-09       Impact factor: 3.210

2.  Safety and efficacy of levetiracetam for critically ill patients with seizures.

Authors:  Karen M Nau; Gavin D Divertie; Alden K Valentino; William D Freeman
Journal:  Neurocrit Care       Date:  2009-01-29       Impact factor: 3.210

3.  How I treat status epilepticus in the Neuro-ICU.

Authors:  Panayiotis N Varelas
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

4.  Intravenous levetiracetam in critically ill children.

Authors:  Faruk Incecik; Ozden O Horoz; Ozlem M Herguner; Dincer Yıldızdas; Seyda Besen; Ilknur Tolunay; Sakir Altunbasak
Journal:  Ann Indian Acad Neurol       Date:  2016 Jan-Mar       Impact factor: 1.383

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.